Compugen Ltd (CGEN) Stock Quote & Options Analysis | Frenzy Capital
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- 52-Week Range
- $1.23 – $3.23
- YTD
- +100.00%
- IV Rank (30D)
- 38.06
- Straddle Price
- $0.75
- P/C Vol Ratio
- 0.01
- Market Cap
- $0.3B
- Exchange
- XNAS
- Market Cap
- $0.3B
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximu…
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | +11.53% | 6 |
| Feb | -12.21% | 6 |
| Mar | -4.02% | 6 |
| Apr | -0.57% | 6 |
| May | +12.97% | 5 |
| Jun | +4.21% | 5 |
| Jul | -9.01% | 5 |
| Aug | -3.19% | 5 |
| Sep | -14.63% | 5 |
| Oct | +5.17% | 5 |
| Nov | -10.56% | 5 |
| Dec | +26.30% | 5 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 78.2 | Overbought |
| MACD | 0.229 | Bullish |
| SMA 50 | $2.22 | Above |
| SMA 200 | $1.77 | Above |
| Bollinger Bands | Neutral | |
| ADX | 47.6 | Strong Trend |
| HV 30 | 52.8% |
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
| Published | Title | Publisher | Sentiment |
|---|---|---|---|
| 2024-07-02 | Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag | Zacks Investment Research | |
| 2024-07-01 | FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease | Zacks Investment Research | |
| 2024-07-01 | Apellis (APLS) Falls on Second Negative CHMP Opinion for GA Drug | Zacks Investment Research | |
| 2024-07-01 | PTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug | Zacks Investment Research | |
| 2024-06-28 | Cogent (COGT) Up on SUMMIT Study Update Post Positive FDA Meeting | Zacks Investment Research | |
| 2024-06-28 | Merck's (MRK) New Pneumococcal Jab Capvaxive Gets CDC Panel Vote | Zacks Investment Research | |
| 2024-06-27 | Novo Nordisk's (NVO) Hypertension Drug Study Fails to Meet Goal | Zacks Investment Research | |
| 2024-06-27 | CASI Pharmaceuticals (CASI) Up on Buyout Offer for China Business | Zacks Investment Research |
- IV Rank (30D)
- 38.06
- IV Rank (7D)
- 38.06
- Avg IV
- 136.2%
- Straddle (30D)
- $0.75
- Straddle (7D)
- $0.75
- P/C Volume
- 0.01
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Enter a ticker to render the implied volatility surface.
- Beta (1Y vs SPY)
- 1.63
- Correlation (SPY)
- 28.3%
- R²
- 0.08
- Ann. Volatility
- 71.9%
- SPY Volatility
- 12.5%
High volatility - stock moves more than market
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.